Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi strong in 1Q despite diabetes slump as Brandicourt starts strategic review

This article was originally published in Scrip

Executive Summary

Sanofi's new CEO Olivier Brandicourt was able to report a strong set of first quarter results just a few weeks after taking the helm, which hardly seems fair to ousted CEO Chris Viehbacher. Sanofi's first quarter sales increased by 2% at constant exchange rates to €8.8bn (12% on a reported basis owing to the weak euro), which was above analysts' expectations. However, its diabetes business is still a major concern.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028600

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel